Compare · NVO vs SION
NVO vs SION
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 941.4x SION ($184.5M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for SION).
- NVO has more recent analyst coverage (25 ratings vs 16 for SION).
- Company
- Novo Nordisk A/S
- Sionna Therapeutics Inc.
- Price
- -
- -
- Market cap
- $173.66B
- $184.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 16
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest SION
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
- Director Ra Capital Management, L.P. sold $21,835,018 worth of shares (3,448,811 units at $6.33) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.
- CFO and CBO Ridloff Elena was granted 94,537 shares, increasing direct ownership by 245% to 133,069 units (SEC Form 4)
- CMO and Head of R&D Mckee Charlotte was granted 100,000 shares, increasing direct ownership by 352% to 128,415 units (SEC Form 4)
- CLO and Head of Program Mgmt. Fitzpatrick Jennifer was granted 56,265 shares (SEC Form 4)
- President & CEO Cloonan Michael was granted 218,050 shares, increasing direct ownership by 40% to 765,393 units (SEC Form 4)
- SEC Form 144 filed by Sionna Therapeutics Inc.
- SEC Form 8-K filed by Sionna Therapeutics Inc.
- Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial